I recently stumbled upon a discussion about a little known, but potentially very serious side effect from Zometa (zoledronic acid), also known as a Bisphosphonate treatment. The side effect, Anterior Uvetis, is an inflammatory condition of the iris of the eye. It is characterized any or all of these symptoms; pain, photophobia (sensitivity to light), [...]
I have had the privilege of working with Leslie Mulkey, an independent video producer on a short "You Tube" video about Provenge. Our hope is that our question, "Should terminally ill patients have access to promising new therapies?" will become a part of the next national presidential debate. You can view our video by clicking [...]
Our brothers in Australia can finally have access to Taxotere! The Pharmaceutical Benefits Scheme (PBS) has finally listed Taxotere for men with hormone refractory prostate cancer. Now, our brothers in Australia will not have to personally pay to obtain their Taxotere. Up until this point, those who were able to afford to pay for Taxotere [...]
Taxotere® (Docetaxel) plus Estramustine Confirmed Superior to Taxotere Alone for Hormone Refractory Prostate Cancer A recent multi-center U.S. clinical trial has concluded that Taxotere and Estramustine improved survival of men with hormone refractory prostate cancer (HRPC) when compared to the standard regimen of Mitoxantrone and Prednisone. In addition, a recent French trial reported that a [...]
Two poster presentations at the ESMO Conference at Lugano this week showed that the drug, called Abiraterone, reduced the levels of prostate specific antigen (PSA) in men who have failed initial treatment and in men who have failed treatment with Taxotere. Abiraterone inhibits the production of male androgens by blocking the enzyme CYP450c17. Without this [...]